Effect of PPAR-γ activation and inhibition on glucose-stimulated insulin release in INS-1e cells

Diabetes

Volumn 53, Issue SUPPL. 3, 2004, Pages

  Santini, Eleonora ^a   Fallahi, Poupak ^a   Ferrari, Silvia Martina ^a   Masoni, Antonio ^a   Antonelli, Alessandro ^a   Ferrannini, Ele ^a,b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b Department of Internal Medicine ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIMETHYL ALPHA (DIMETHOXYPHOSPHINYL) 4 CHLOROBENZYL PHOSPHATE; GLUCOSE; INSULIN; MIFOBATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT; RO 4389679000001; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL CULTURE; CELL LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG RECEPTOR BINDING; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR INTRINSIC ACTIVITY;

ANIMALS; CELL LINE; GLUCOSE; HUMANS; INSULIN; ISLETS OF LANGERHANS; KINETICS; PPAR GAMMA; RATS;

EID: 9444260922     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.suppl_3.S79     Document Type: Conference Paper

References (25)

1. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
2. Lehmann JM, Moore RB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12906, 1995
3. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
4. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, Saruta T: Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102-1107, 1999
5. Fujiwara T, Yoshioka S, Yosluoka T, Ushiyama I, Horikoshi H: Characterization of new oral anti-diabetic agent CS-045; studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
6. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H: Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent troglitazone in NIDDM subjects. Diabetes Care 15:193-203, 1992
8. Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y: Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24-30, 1995
9. 2+ influx. J Endocrinol 150:107-111, 1996
10. Ohtani K, Shimizu H, Sato N, Mori M: Troglitazone (CS-045) inhibits β-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells. Endocrinology 139:172-178, 1998
11. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 40:1213-1218, 1991
12. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997
13. Kawai T, Hirose H, Seto Y, Fujita H, Saruta T: Chronic effects of different fatty acids and leptin in INS-1 cells. Diabetes Res Clin Pract 51:1-8, 2001
14. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S: Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 286: E560-E567, 2004
15. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 44:863-870, 1995
16. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
17. McGarry JD, Dobbins RL: Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42:128-138, 1999
18. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD, McGarry JD: The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 100:398-403, 1997
19. 2+. Diabetes 47:352-357, 1998
20. Kawai T, Hirose H, Seto Y, Pujita H, Pujita H, Ukeda K, Saruta T: Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. Diabetes Res Clin Pract 56:83-92, 2002
21. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W: A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628-2644, 2002
22. Inoue Y, Tanigawa K, Nakamura S, Xu G, Kawaguchi M, Kato Y, Tamura K: Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats. Diabetes Res Clin Pract, 27:19-26, 1995
23. Prigeon RL, Kahn SE, Porte D Jr. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:819-823, 1998
24. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H: Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704-711, 2000
25. Klewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94:4318-4323, 1997